Crotaline snake antivenom

Drug Profile

Crotaline snake antivenom

Alternative Names: Anavip; Crotaline snake antivenin - Rare Disease Therapeutics

Latest Information Update: 01 Jun 2010

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Instituto Bioclon; Rare Disease Therapeutics
  • Developer Rare Disease Therapeutics
  • Class Antivenins; Fab fragments
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Snake venom poisoning

Highest Development Phases

  • No development reported Snake venom poisoning

Most Recent Events

  • 20 Jun 2005 Phase-II clinical trials in Snake venom poisoning in USA (Injection)
  • 20 Jan 2004 Crotaline snake antivenom [Anavip™] has received Orphan Drug Status for Snake venom poisoning in USA.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top